文献速递胸部肿瘤

评估血液肿瘤突变负荷作为非小细胞肺癌免疫治疗潜在生物标志物:基于下一代测序癌症基因面板的研究

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
PubMed 文献 · JAMA Oncol · 2019-01-01

本研究设计并验证了150基因癌症基因面板NCC-GP150,用于估算血液肿瘤突变负荷(bTMB)。在48例晚期NSCLC患者中,bTMB与组织TMB(tTMB)的Spearman相关系数为0.62。在50例接受抗PD-1/PD-L1治疗的患者中,bTMB≥6与更优的无进展生存期(HR 0.39;95%CI 0.18-0.84;log-rank P=0.01)和客观缓解率(39.3% vs 9.1%;P=0.02)相关。

要点

  • NCC-GP150估算的bTMB与WES测定的tTMB相关系数为0.62。
  • bTMB≥6与抗PD-1/PD-L1治疗后的PFS改善相关(HR 0.39;95%CI 0.18-0.84)。
  • bTMB≥6组客观缓解率为39.3%,bTMB<6组为9.1%(P=0.02)。

核心结论

  • 研究提示NCC-GP150 panel可用于估算bTMB,bTMB可能作为NSCLC患者接受抗PD-1/PD-L1治疗临床获益的潜在生物标志物。

研究设计与样本

  • 队列研究,设计NCC-GP150 panel并利用癌症基因组图谱数据库进行虚拟验证。
  • 在48例晚期NSCLC患者的配对血液和组织样本中评估bTMB与tTMB的相关性。
  • 在50例晚期NSCLC独立队列中评估bTMB区分抗PD-1/PD-L1治疗获益患者的能力。
  • 研究时间为2016年7月19日至2018年4月20日。

主要发现

  • 包含150个基因的CGP与WES估算TMB具有稳定相关性(中位r²=0.91;四分位距0.89-0.92),纳入同义突变时中位r²=0.92(四分位距0.91-0.93)。
  • NCC-GP150估算的TMB与WES估算TMB的相关性高于大多数随机抽取的150基因panel。
  • NCC-GP150估算的bTMB与配对tTMB相关性良好(Spearman相关系数=0.62)。
  • bTMB≥6与更优的无进展生存期相关(HR 0.39;95%CI 0.18-0.84;log-rank P=0.01)。
  • bTMB≥6组客观缓解率为39.3%(95%CI 23.9%-56.5%),bTMB<6组为9.1%(95%CI 1.6%-25.9%),P=0.02。

关键数值与推荐

  • bTMB阈值6用于区分抗PD-1/PD-L1治疗后的无进展生存期和客观缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be explored. OBJECTIVES: To explore the optimal gene panel size and algorithm to design a CGP for TMB estimation, evaluate the panel reliability, and further validate the feasibility of bTMB as a clinical actionable biomarker for immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, a CGP named NCC-GP150 was designed and virtually validated using The Cancer Genome Atlas database. The correlation between bTMB estimated by NCC-GP150 and tissue TMB (tTMB) measured by WES was evaluated in matched blood and tissue samples from 48 patients with advanced NSCLC. An independent cohort of 50 patients with advanced NSCLC was used to identify the utility of bTMB estimated by NCC-GP150 in distinguishing patients who would benefit from anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1) therapy. The study was performed from July 19, 2016, to April 20, 2018. MAIN OUTCOMES AND MEASURES: Assessment of the Spearman correlation coefficient between bTMB estimated by NCC-GP150 and tTMB calculated by WES. Evaluation of the association of bTMB level with progression-free survival and response to anti-PD-1 and anti-PD-L1 therapy. RESULTS: This study used 2 independent cohorts of patients with NSCLC (cohort 1: 48 patients; mean [SD] age, 60 [13] years; 15 [31.2%] female; cohort 2: 50 patients; mean [SD] age, 58 [8] years; 15 [30.0%] female). A CGP, including 150 genes, demonstrated stable correlations with WES for TMB estimation (median r2 = 0.91; interquartile range, 0.89-0.92), especially when synonymous mutations were included (median r2 = 0.92; interquartile range, 0.91-0.93), whereas TMB estimated by the NCC-GP150 panel found higher correlations with TMB estimated by WES than most of the randomly sampled 150-gene panels. Blood TMB estimated by NCC-GP150 correlated well with the matched tTMB calculated by WES (Spearman correlation = 0.62). In the anti-PD-1 and anti-PD-L1 treatment cohort, a bTMB of 6 or higher was associated with superior progression-free survival (hazard ratio, 0.39; 95% CI, 0.18-0.84; log-rank P = .01) and objective response rates (bTMB ≥6: 39.3%; 95% CI, 23.9%-56.5%; bTMB <6: 9.1%; 95% CI, 1.6%-25.9%; P = .02). CONCLUSIONS AND RELEVANCE: The findings suggest that established NCC-GP150 with an optimized gene panel size and algorithm is feasible for bTMB estimation, which may serve as a potential biomarker of clinical benefit in patients with NSCLC treated with anti-PD-1 and anti-PD-L1 agents.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Duan J, Cai S, et al. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol. 2019. PMID: 30816954. doi:10.1001/jamaoncol.2018.7098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。